Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2309 - Quality of life (QoL) analyses in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) treated with first-line FOLFOX-4 ± cetuximab in the phase 3 TAILOR trial

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Colon and Rectal Cancer

Presenters

Tianshu Liu

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

T. Liu1, J. Li2, J. Xu3, L. Wang4, Y. Cheng5, W. Chen6, J. Chen7, C.P. Pescott8, S. Qin9

Author affiliations

  • 1 Medical Oncology, Zhongshan Hospital, Fudan University, 200032 - Shanghai/CN
  • 2 Medical Oncology, Tongji University Shanghai East Hospital, Shanghai/CN
  • 3 Medical Oncology, 307 Hospital of PLA, Beijing/CN
  • 4 Medical Oncology, Shanghai First People's Hospital, 201620 - Shanghai/CN
  • 5 Medical Oncology, Jilin Cancer Hospital, Jilin/CN
  • 6 R&d Global Biostatistics & Epidemiology, Merck Serono (Beijing) Pharmaceutial R&D Co., Ltd, Beijing/CN
  • 7 Medical Affairs, Merck Serono (Beijing) Pharmaceutial R&D Co., Ltd, Beijing/CN
  • 8 Global Evidence & Value Development, Merck KGaA, 64293 - Darmstadt/DE
  • 9 Medical Oncology, Nanjing Bayi Hospital, 210002 - Nanjing/CN
More

Resources

Abstract 2309

Background

In the phase 3 TAILOR trial, adding cetuximab to first-line FOLFOX-4 significantly improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in patients with RAS wt mCRC. Here we present QoL analyses.

Methods

TAILOR is a randomized phase 3 trial that includes a modified intention-to-treat population of 393 patients from China with RAS wt mCRC treated with FOLFOX-4 ± cetuximab. The primary endpoint of TAILOR is PFS based on independent review; secondary endpoints include OS, ORR, and QoL. QoL is investigated using the European Organisation for Research and Treatment of Cancer QoL questionnaire core-30 (EORTC QLQ-C30). QoL assessments were planned to be performed at baseline, every 8 weeks of treatment thereafter, and at the final tumor assessment. Patients with RAS wt tumors are considered evaluable for QoL if they provide ≥ 1 evaluable EORTC QLQ-C30 from screening to end of evaluation. Pattern-mixture modeling is used to compare QoL between treatment groups by taking into account dropout pattern and other covariates.

Results

Among 393 patients with RAS wt tumors, 390 were evaluable for QoL. Before adjustment for several factors (treatment, time, dropout pattern, age, sex, ECOG performance status, number of disease sites, liver-only metastases, and interaction between treatment and dropout pattern), global health status/QoL showed slightly more deterioration in the FOLFOX-4 + cetuximab arm vs FOLFOX-4 arm; however, when these factors were included in the analysis model, the difference between treatment groups was not considered clinically relevant. Similar findings were obtained upon analogous evaluation of social functioning, an individual QoL-related dimension of interest in mCRC.

Conclusions

Adding cetuximab to first-line FOLFOX-4 significantly improved PFS, OS, and ORR without negatively impacting QoL in TAILOR study patients with RAS wt mCRC, consistent with observations from earlier cetuximab pivotal trials. These observations confirm cetuximab in combination with FOLFOX-4 as a standard-of-care first-line treatment regimen for patients with RAS wt mCRC.

Clinical trial identification

NCT01228734

Legal entity responsible for the study

Merck KGaA, Darmstadt, Germany

Funding

Merck KGaA, Darmstadt, Germany

Disclosure

J. Li: Research funding: Merck Inc., Roche-Peru. W. Chen, J. Chen: Employment: Merck Serono. C.P. Pescott: Employment: Merck KGaA, Darmstadt, Germany. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.